Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

I. Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; H. Cartwright, Thomas; D. Hainsworth, John; Heim, W.; Berlin, Jordan; David Baron, Ari; Griffing, S.; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; W. Ross, Robert; F. Kabbinavar, Fairooz

doi:10.1056/nejmoa032691

Public

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Published in New England Journal of Medicine • Jun 2, 2004

Authors:

Herbert I. Hurwitz

Louis Fehrenbacher

William Novotny

Abstract

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorect...

Subject

Medicine

Irinotecan

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!